36 related articles for article (PubMed ID: 23659451)
21. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
22. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation.
Momeny M; Khorramizadeh MR; Ghaffari SH; Yousefi M; Yekaninejad MS; Esmaeili R; Jahanshiri Z; Nooridaloii MR
Eur J Pharmacol; 2008 Sep; 591(1-3):13-20. PubMed ID: 18599034
[TBL] [Abstract][Full Text] [Related]
23. Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries.
Ding X; Park YN; Taltavull TC; Thung SN; Jin X; Jin Y; Trung NS; Edamoto Y; Sata T; Abe K
Jpn J Infect Dis; 2003 Feb; 56(1):12-8. PubMed ID: 12711820
[TBL] [Abstract][Full Text] [Related]
24. Antrodia cinnamomea fruiting bodies extract suppresses the invasive potential of human liver cancer cell line PLC/PRF/5 through inhibition of nuclear factor kappaB pathway.
Hsu YL; Kuo PL; Cho CY; Ni WC; Tzeng TF; Ng LT; Kuo YH; Lin CC
Food Chem Toxicol; 2007 Jul; 45(7):1249-57. PubMed ID: 17316946
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-κB expressions may play an important role in silibinin-induced response.
Yousefi M; Ghaffari SH; Soltani BM; Nafissi S; Momeny M; Zekri A; Behmanesh M; Alimoghaddam K; Ghavamzadeh A
Neurochem Res; 2012 Sep; 37(9):2053-63. PubMed ID: 22717697
[TBL] [Abstract][Full Text] [Related]
26. Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells.
Ghasemi R; Ghaffari SH; Momeny M; Pirouzpanah S; Yousefi M; Malehmir M; Alimoghaddam K; Ghavamzadeh A
Nutr Cancer; 2013; 65(4):590-9. PubMed ID: 23659451
[TBL] [Abstract][Full Text] [Related]
27. Molecular targets for therapy of hepatitis B virus-induced hepatocellular carcinoma.
Tharayil VS; Roberts LR
Minerva Gastroenterol Dietol; 2006 Dec; 52(4):387-406. PubMed ID: 17108869
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma.
Kew MC
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():144-52. PubMed ID: 21199526
[TBL] [Abstract][Full Text] [Related]
29. Early molecular and genetic determinants of primary liver malignancy.
Feitelson MA; Pan J; Lian Z
Surg Clin North Am; 2004 Apr; 84(2):339-54. PubMed ID: 15062649
[TBL] [Abstract][Full Text] [Related]
30. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
Xue KX
Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
[TBL] [Abstract][Full Text] [Related]
31. An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma.
Rawat D; Shrivastava S; Naik RA; Chhonker SK; Mehrotra A; Koiri RK
Anticancer Agents Med Chem; 2018; 18(13):1838-1859. PubMed ID: 29866017
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
